Limited utility of fluorescence in situ hybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 601-605

  Seegmiller, Adam C ^a   Wasserman, Allison ^a   Kim, Annette S ^a   Kressin, Megan K ^a,b   Marx, Edward R ^c   Zutter, Mary M ^a   Mosse, Claudio A ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Tennessee Valley Healthcare System   (United States)

Author keywords

Acute myeloid leukemia; Diagnosis; Fluorescence in situ hybridization; Karyotype; Myelodysplastic syndrome; Test utilization

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPE; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; YOUNG ADULT;

EID: 84890546919     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.801470     Document Type: Article

References (21)

1. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008. pp. 88-93
2. ArberDA, Brunning RD, Orazi A, et al. Acute myeloid leukemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 124-126
3. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465
4. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003 ; 21 : 256-265
5. Rigolin GM, Bigoni R, Milani R, et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 2001; 15:1841-1847
6. Romeo M, Chauffaille Mde L, Silva MR, et al. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res 2002 ; 26 : 993-996
7. Beyer V Castagne C, Muhlematter D, et al. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet 2004;152:29-41
8. Mallo M, Arenillas L, Espinet B, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q. Haematologica 2008 ; 93 : 1001-1008
9. Ketterling RP, WyattWA,VanWierSA, et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of "FISH panel testing" and M-FISH. Leuk Res 2002;26:235-240
10. Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 2003;27:1085-1090
11. Yang W, Stotler B, Sevilla DW, et al. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res 2010;34:420-425
12. Pitchford CW, Hettinga AC, Reichard KK. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. Am J Clin Pathol 2010 ; 133 : 260-264
13. Coleman JF, Theil KS, Tubbs RR, et al. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. Am J Clin Pathol 2011;135:915-920
14. Jiang H, Xue Y, Wang Q, et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. Leuk Res 2012;36:448-452
15. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009 ; 42 : 377-381
16. Wolff DJ, Bagg A, Cooley LD, et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn 2007;9:134-143
17. Wiktor AE, Van Dyke DL, Stupca PJ, et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 2006 ; 8 : 16-23
18. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: International System of Human Cytogenetic Nomenclature. Basel: S. Karger AG; 2009
19. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA 2012 ; 307 : 1513-1516
20. Brody H. From an ethics of rationing to an ethics of waste avoidance. N Engl J Med 2012 ; 366 : 1949 - 1951
21. Seegmiller AC, Kim AS, Mosse CA, et al. Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach. Am J Clin Pathol 2013;in press.